Treating Nondementia Illnesses in Patients With Dementia

Physicians increasingly are called on to provide primary care for the growing population of people with Alzheimer-type dementia. However, little attention has been paid to the care of nondementia illnesses in this group of patients. To illustrate how presence of dementia can alter the risk-benefit r...

Full description

Saved in:
Bibliographic Details
Published in:JAMA : the journal of the American Medical Association 2000-06, Vol.283 (24), p.3230-3235
Main Authors: Brauner, Daniel J, Muir, J. Cameron, Sachs, Greg A
Format: Article
Language:English
Subjects:
Bioethics
Biological and medical sciences
Case studies
Communication
Decision Making
Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
Dementia
Dementia - complications
Drug Therapy
Ethics, Medical
Humans
Illnesses
Medical sciences
Mental Competency
Neurology
Nontherapeutic Human Experimentation
Patient Compliance
Physician-Patient Relations
Primary care
Primary Health Care
Risk
Risk Assessment
Therapeutic Human Experimentation
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Physicians increasingly are called on to provide primary care for the growing population of people with Alzheimer-type dementia. However, little attention has been paid to the care of nondementia illnesses in this group of patients. To illustrate how presence of dementia can alter the risk-benefit ratio of treatment of a common medical problem, we present a case study in which a patient with dementia developed disastrous adverse effects to a drug commonly used to treat osteoporosis. This case and 2 composite vignettes illuminate how presence of dementia should influence the decision-making process for treatment of nondementia illnesses. We address issues such as decreased decision-making capacity, problems with reporting adverse effects, decreased cognition leading to problems with treatment adherence, and the role of screening and basic questions about acceptable burdens of treatments in patients with limited prognosis. We suggest ways to improve communication with patients with dementia in an effort to minimize complications and improve care, as well as policy changes to include patients with dementia in clinical trials.
ISSN:0098-7484
1538-3598
DOI:10.1001/jama.283.24.3230